Eric Greenspan

JANUARY 24, 2016

After being what I assume is the subject of one or more of Seth David’s emotionally charged blog posts, I’ve decided it’s time to respond. This blog post is for information purposes only and my only intention is to move forward. In 2012, my company plundered and it was horrific…bygones. I did the rest.

Content 100

Content Blogging Burbank Course 100

Xconomy

JULY 26, 2016

LendingClub helped to pioneer the model, saying in November 2012 that it had surpassed $1 billion in loans issued since 2006, when it was founded. billion in loans since 2012, when its business “morphed” into an alternative lender, according to founder and CEO Dave Gilbert. million in 2012 to more than $59 million in 2015.

San Diego 40

San Diego Help Software Review Funding 40

Xconomy

JULY 26, 2016

LendingClub helped to pioneer the model, saying in November 2012 that it had surpassed $1 billion in loans issued since 2006, when it was founded. billion in loans since 2012, when its business “morphed” into an alternative lender, according to founder and CEO Dave Gilbert. million in 2012 to more than $59 million in 2015.

Software Review 40

Software Review San Diego Funding Customer 40

Xconomy

OCTOBER 27, 2016

Venture capital firms have increased their agtech investments by 80 percent since 2012, bringing total VC investment in the sector to a total of $3 billion in 2015, according to a new report from Boston Consulting Group and AgFunder, an online investment marketplace for agriculture technology.

Venture Capital 40

Venture Capital Pricing Invest Report 40

Xconomy

OCTOBER 14, 2016

That means in three months, Bristol has lost a third of its value, equivalent to about $40 billion in market capitalization. Illumina fended off a hostile takeover bid from Roche back in February 2012, and over the next three years shares went from about $51 apiece to as high as $219.30 in July 2015. The reason?

News 40

News San Diego Incubator Research 40

Xconomy

OCTOBER 18, 2016

Sales of both drugs, ivacaftor (Kalydeco) and the combo pill ivacaftor-lumacaftor (Orkambi), reached almost $1 billion in 2015 and are growing. In August 2014—just six months after moving into its new glass towers —Vertex announced plans to take telaprevir off the market. But the drugs aren’t cures, and competition looms.

Startup 40

Startup Research Sales Organization 40

Both Sides of the Table

OCTOBER 18, 2015

There is a lot of uncertainty about the state of the private, high-growth technology markets and the venture capital markets that underpin them. There is nobody to blame for this abandonment of common sense – it is simply the market being the market and we’re doomed to repeat history. It’s just a market.

Venture Capital 150

Venture Capital Pricing Platform Marketing 150